Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study

Published:2008-04-08 Issue:8 Volume:100 Page:552-562
ISSN:0027-8874
Container-title:JNCI Journal of the National Cancer Institute
language:en
Short-container-title:JNCI Journal of the National Cancer Institute

Author:

von Minckwitz G.,Kummel S.,Vogel P.,Hanusch C.,Eidtmann H.,Hilfrich J.,Gerber B.,Huober J.,Costa S. D.,Jackisch C.,Loibl S.,Mehta K.,

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/100/8/552/7683998/djn089.pdf

Reference18 articles.

1. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

2. Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: Further results from a randomised controlled trial

3. Adjuvant Docetaxel for Node-Positive Breast Cancer

4. Phase II Study of Docetaxel, Doxorubicin, and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer

5. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrasound and diffuse optical tomography-transformer model for assessing pathological complete response to neoadjuvant chemotherapy in breast cancer;Journal of Biomedical Optics;2024-07-24

2. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-05-14

3. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE);ESMO Open;2024-05

4. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis;European Journal of Cancer;2023-09

5. Breast cancer: treatment response assessment with FDG-PET/CT in the neoadjuvant and in the metastatic setting;Clinical and Translational Imaging;2023-07-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3